StemSource Migrates to the Device World
This article was originally published in Start Up
Executive Summary
A rudimentary orthobiologic rationale forms the basis of Macropore Biosurgery's acquisition of StemSource. Macropore wants to develop the devices needed to collect adipose stem cells (StemSource's technology) in the operating room for surgeons to administer them to help rebuild damaged organs and tissue. While financially modest, the deal is one of the first forays to bring the medical device and cell therapy worlds closer.